Neoadjuvant chemotherapy enriches for drug-tolerant persisters in PDAC
Resected pancreatic cancer treated pre-operatively with chemotherapy is enriched for cells that co-express GATA6, KRT17 and CYP3A. Persistent expression of GATA6hi and KRT17hi is associated with poor survival after treatment with mFOLFIRINOX, but not gemcitabine. CYP3A-expressing drug detoxification...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2023
|
| In: |
Nature cancer
Year: 2023, Volume: 4, Issue: 9, Pages: 1226-1227 |
| ISSN: | 2662-1347 |
| DOI: | 10.1038/s43018-023-00629-5 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s43018-023-00629-5 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s43018-023-00629-5 
|
| Author Notes: | P. Bailey, J. Neoptolemos |
| Summary: | Resected pancreatic cancer treated pre-operatively with chemotherapy is enriched for cells that co-express GATA6, KRT17 and CYP3A. Persistent expression of GATA6hi and KRT17hi is associated with poor survival after treatment with mFOLFIRINOX, but not gemcitabine. CYP3A-expressing drug detoxification pathways metabolize the prodrug irinotecan, a constituent of mFOLFIRINOX, leading to persistent drug tolerance. |
|---|---|
| Item Description: | Gesehen am 16.10.2023 |
| Physical Description: | Online Resource |
| ISSN: | 2662-1347 |
| DOI: | 10.1038/s43018-023-00629-5 |